Ionis Pharmaceuticals, Inc. (IONS)
Health Care ยท Pharmaceutical Preparations
Ionis Pharmaceuticals, Inc. (IONS) is listed on Nasdaq, where its shares have traded since May 17, 1991. SentiSense covers Ionis Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Brett P. Monia is its chief executive officer. The company reports 1,402 employees, and its corporate website is www.ionis.com.
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 499 institutions reported holding IONS, with 179.6 million shares worth $14.3 billion in aggregate. The largest reported holders were FMR, Capital Group and Vanguard. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on IONS
- IONS sentiment: whether news and social coverage of Ionis Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- IONS ownership: all 499 reporting institutions, plus insider and congressional trades.
- IONS financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Ionis Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Ionis Pharmaceuticals, Inc. do?
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs.
What sector is IONS in?
SentiSense classifies Ionis Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does IONS stock trade?
Ionis Pharmaceuticals, Inc. (IONS) is listed on Nasdaq, where its shares have traded since May 17, 1991.
Who is the CEO of Ionis Pharmaceuticals, Inc.?
Brett P. Monia is the chief executive officer of Ionis Pharmaceuticals, Inc..